Wang Hong-Yan, Lin Li, Fu Wei, Yu Hui-Yuan, Yu Ning, Tan Li-Si, Cheng Jya-Wei, Pan Ya-Ping
Department of Periodontics and Oral Biology, School of Stomatology, China Medical University, Shenyang, 110002, China.
Department of Pharmacy, Tongji Hospital Affiliated with Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
BMC Complement Altern Med. 2017 Aug 29;17(1):426. doi: 10.1186/s12906-017-1931-9.
P-113 (AKRHHGYKRKFH-NH2) is a 12-amino-acid histidine-rich peptide derived from histatin 5 that is highly degradable in high salt concentrations and biological fluids such as serum, plasma and saliva. Nal-P-113, a novel antimicrobial peptide whose histidine residues are replaced by the bulky amino acids β-naphthylalanine, causes the antimicrobial peptide to retain its bactericidal activity even in physiological environments. This study evaluated the effect of the novel antimicrobial peptide Nal-P-113 in a rat periodontitis model and the mechanisms of action of Nal-P-113 for suppressing periodontitis.
Periodontitis was induced in mandibular first molars in rats receiving a ligature and infected with Porphyromonas gingivalis. Animals were randomly divided into six groups: a, P. gingivalis W83 alone; b, P. gingivalis W83 with 6.25 μg/mL of Nal-P-113; c, P. gingivalis W83 with 25 μg/mL of Nal-P-113; d, P. gingivalis W83 with 100 μg/mL of Nal-P-113; e, P. gingivalis W83 with 400 μg/mL of Nal-P-113; and f, control without P. gingivalis W83 or Nal-P-113. Morphometric analysis was used to evaluate alveolar bone loss. Microbiological assessment of the presence of Porphyromonas gingivalis and total bacteria was performed using absolute quantitative real-time PCR and scanning electron microscopy. Gingival tissue was collected for western blot and immunohistochemical assays of IL-1β and TNF-α levels.
Alveolar bone loss was inhibited by 100 μg/mL or 400 μg/mL of Nal-P-113 compared to the control group (P < 0.05). Lower amounts of P. gingivalis and total bacteria were found in groups d and e compared with group a (P < 0.05). A decrease in the levels of IL-1β and TNF-α was detected in group d and group e compared to the control group (P < 0.05). The amount of P. gingivalis was positively correlated with IL-1β and TNF-α expression in periodontal tissue (P < 0.05).
Nal-P-113 exhibited protective effects on Porphyromonas gingivalis-induced periodontitis in rats by limiting the amount of bacteria and modulating IL-1β and TNF-α production. The use of Nal-P-113 in vivo might serve as a beneficial preventive or therapeutic approach for periodontitis.
P-113(AKRHHGYKRKFH-NH2)是一种由组蛋白5衍生而来的富含组氨酸的12氨基酸肽,在高盐浓度以及血清、血浆和唾液等生物体液中极易降解。新型抗菌肽Nal-P-113,其组氨酸残基被大分子氨基酸β-萘丙氨酸取代,使得该抗菌肽即使在生理环境中也能保持杀菌活性。本研究评估了新型抗菌肽Nal-P-113在大鼠牙周炎模型中的作用效果以及其抑制牙周炎的作用机制。
通过结扎并感染牙龈卟啉单胞菌诱导大鼠下颌第一磨牙发生牙周炎。将动物随机分为六组:a组,仅牙龈卟啉单胞菌W83;b组,牙龈卟啉单胞菌W83加6.25μg/mL的Nal-P-113;c组,牙龈卟啉单胞菌W83加25μg/mL的Nal-P-113;d组,牙龈卟啉单胞菌W83加100μg/mL的Nal-P-113;e组,牙龈卟啉单胞菌W83加400μg/mL的Nal-P-113;f组,无牙龈卟啉单胞菌W83或Nal-P-113的对照组。采用形态计量分析评估牙槽骨吸收情况。使用绝对定量实时聚合酶链反应和扫描电子显微镜对牙龈卟啉单胞菌和总细菌的存在情况进行微生物学评估。收集牙龈组织用于白细胞介素-1β(IL-1β)和肿瘤坏死因子-α(TNF-α)水平的蛋白质免疫印迹和免疫组织化学分析。
与对照组相比,100μg/mL或400μg/mL的Nal-P-113可抑制牙槽骨吸收(P<0.05)。与a组相比,d组和e组中牙龈卟啉单胞菌和总细菌数量较少(P<0.05)。与对照组相比,d组和e组中IL-1β和TNF-α水平降低(P<0.05)。牙龈卟啉单胞菌数量与牙周组织中IL-1β和TNF-α表达呈正相关(P<0.05)。
Nal-P-113通过限制细菌数量和调节IL-1β和TNF-α的产生,对牙龈卟啉单胞菌诱导的大鼠牙周炎具有保护作用。在体内使用Nal-P-113可能是一种有益的牙周炎预防或治疗方法。